Skip to main content

Articles

Payers' Guide, FDA Approvals
Glyxambi (Empagliflozin/Linagliptin): A Dual- Acting Oral Medication Approved for the Treatment of Patients with Type 2 Diabetes
Read More
Payers' Guide, FDA Approvals
Lenvima (Lenvatinib), a Multireceptor Tyrosine Kinase Inhibitor, Approved by the FDA for the Treatment of Patients with Differentiated Thyroid Cancer
Read More
Payers' Guide, FDA Approvals
Opdivo (Nivolumab): Second PD-1 Inhibitor Receives FDA Approval for Unresectable or Metastatic Melanoma
Read More
Mitigating the Burden of Type 2 Diabetes: Challenges and Opportunities
Read More
Interview with the Innovators
Unclear Diagnoses in Patients with Metastatic Disease
Read More
Interview with the Innovators
The bioT3 platform
Read More
Interview with the Innovators
Clinical Validation of CancerTYPE ID
Read More
Interview with the Innovators
CancerTYPE ID in the Clinic
Read More
Interview with the Innovators
CancerTREATMENT NGS+ in the Clinic
Read More
Interview with the Innovators
Managing Costs in Oncology Care
Read More
Page 138 of 244
Results 1371 - 1380 of 2434